Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO-2 phase 3 trial of KarXT + KarX-EC for agitation associated with Alzheimer's disease
MOH_2025-09-21_014354Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trospium and KarX-EC in Alzheimer's disease (AD) (2 arms), sponsored by Bristol Myers Squibb. Started Jun 2025; status: recruiting.
02
Drugs
trospiumKarX-EC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2025-09-21_014354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-21_014354.